Tag Archives: winners

RESI San Francisco Innovation Challenge – Check Out the Winners

11 Jan

By Nono Hu, Director of Marketing, LSN

RESI San Francisco 2018 was the biggest Redefining Early Stage Investments event yet. In a highly competitive RESI Innovation Challenge we saw novel technologies represented from the therapeutics, medtech, diagnostics, and healthcare IT verticals – we know it was tough for RESI attendees to choose how to allocate their 5 RESI “investment” tokens! We wish all our finalists the best in bringing their products forward toward commercialization, but there could only be 3 top prize winners.

First Place: CorInnova

With a $6 million lead investment from the UK-based Wellcome Trust ($26 billion in assets), CorInnova is developing an innovative minimally invasive cardiac assist device to treat heart failure. The collapsible soft robotic direct cardiac compression device, deployed minimally invasively into the pericardial space around the heart, does not touch the blood. The device should reduce hospital length of stay from 30 to 4 days and adverse events vs. LVADS by 40%. It will expand the eligible patient population 3 to 4X to an addressable market of up to $14 billion. CorInnova has a world-class team. First-in-human trials are anticipated to begin in 18 months. Three similar cardiac companies with only 10 patients’ data sold for $250 to $400 million in cash.

Boris Leschinsky, Vice President of Product Development,CorInnova | Dennis Ford, CEO, Life Science Nation | William Altman, CEO, CorInnova | Keith Svagerko, Vice President, Business Development, CorInnova

 

Second Place: ImmunoBiochem Corporation

ImmunoBiochem is a privately held biopharmaceutical company solving the problem of tumor heterogeneity by targeting unique proteins enriched in the secretomes of cancer cells with Antibody Drug Conjugates (ADCs) – a promising class of biological anticancer therapeutics. ImmunoBiochem has identified a class of molecular targets that are secreted by cancer cells, but not healthy cells, and possess unique properties enabling the highly-selective delivery of toxic payloads to cancer cells, while leaving normal cells unharmed. ImmunoBiochem’s next-generation biologics aim to offer a superior safety profile and broad therapeutic window. Lead candidate, IMB-212, is aimed at a well-characterized cancer biomarker supported by a wealth of clinical data, and is being developed for Triple-Negative Breast Cancer (TNBC) – an aggressive disease for which no targeted biologics treatment options are available.

Dennis Ford, CEO, Life Science Nation | Anton Neschadim, CEO, ImmunoBiochem | Lucy Parkinson, Director of Investor Research, LSN

 

Third Place: Biorez

Biorez is an early-stage regenerative medicine company developing a bioresorbable scaffold for ACL reconstruction. Despite over 400,000 procedures each year, current surgical options are limited to autograft tissue, which requires a patient to sacrifice their own tendon, or allograft tissue, which is harvested from cadavers and has a higher failure rate. There is a large, unmet clinical need for a consistent, off-the-shelf device for ligament regeneration. The Biorez device provides the necessary strength to support physical activity, while its highly porous, proprietary structure facilitates a patient’s own cells to follow the scaffold and regenerate new functional tissue. The company is supported by early-stage VC investors, world-class scientific advisors, and a dedicated team to commercialize this exciting technology.

Dennis Ford, CEO, Life Science Nation | Kevin Rocco, CEO, Biorez | Lucy Parkinson, Director of Investor Research, LSN

Thank you to all who competed in the RESI JPM Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies. Welcome to join our upcoming RESI on MaRS event on April 10th, register now.

RESI NYC 2017 Innovation Challenge – Winners Announced

16 Nov

By Natasha Eldridge, Director of RESI Conference Series, LSN

natasha-wp-newYesterday, we held the Redefining Early Stage Investments (RESI) conference in New York for the first time, and 36 finalists competed for “investment” tokens from the RESI audience. These finalists included companies developing novel drugs or devices, new diagnostics and healthcare IT applications. All of these companies have the potential to revolutionize medicine, but there could only be 3 top prize winners.

First Place: Sen-Jam Pharma

Sen-Jam Pharmaceutical is reimaging health through innovation. Sen-Jam’s Exulta™ asset, a fixed-dose novel combination therapy, provides opioid free pain relief with GI protection for extended use. Exulta™ can stabilize the innate immune system by modulating histamines, prostaglandins and regulating pro-inflammatory cytokines. Exulta™ can also attenuate glial cell activity. Exulta’s platform can be used for multiple indications: reducing opioid induced hyperalgesia, tolerance and dependence for all chronic opioid users, reducing symptoms of opioid withdrawal, treatment of arthritis, reducing common cold symptoms, reducing alcohol hangover symptoms, and preventing symptoms associated with vaccine administration. Exulta™ has been shown in volunteers to reduce symptoms associated with the innate immune response by 60-90% in over 500 dosing events without adverse effects.

Jim Iversen, CEO & COO, Sen-Jam Pharmaceutical | Natasha Eldridge, Director of RESI Conference Series, LSN | Thomas Dahl, Head of Product Development & Regulatory Affairs, Sen-Jam Pharmaceutical | Lucy Parkinson, Director of Investor Research, LSN

Second Place: Bioharmony Therapeutics

Bioharmony Therapeutics is an early-stage biotechnology company developing next-gen antimicrobial therapies for lethal drug-resistant bacterial infections. We are exploiting millions of year of phage-bacteria evolution to develop lysins, enzymes produced by phages that rapidly kill bacteria and have a very low chance of developing resistance. Our lead product targets infections caused by Acinetobacter baumannii, a MDR-pathogen that poses the greatest threat to human health. Our pipeline targets infections caused by other Gram-negative bacteria such as E.coli and Klebsiella, for use in UTI, pneumonia and sepsis.

Chandrabali Ghose, Founder & CEO, Bioharmony Therapeutics | Natasha Eldridge, Director of RESI Conference Series, LSN | Lucy Parkinson, Director of Investor Research, LSN

Third Place: Mirimus

Mirimus is engaged in the design, development and pioneering of new genome editing technologies to develop animal models that are crucial for the preclinical evaluation of new therapeutics. We are a high-tech business unlike any other with expertise in RNAi technologies critical for development of animal models that can pave the way we develop drugs, by pin-pointing potential toxicities and guiding the development of safer, more effective therapeutics. We are revolutionizing the creation of animal models by synergzing RNAi and CRISPR/Cas9 technologies for development of mice, rats and higher organisms.

Prem Premsrirut, Founder & CEO, Mirimus | Lucy Parkinson, Director of Investor Research, LSN | Natasha Eldridge, Director of RESI Conference Series, LSN

If you missed out on the opportunity to compete in the RESI NYC Innovation Challenge, we’d be happy to take your application for our upcoming San Francisco event on January 9th.

Apply for RESI San Francisco 2018 Innovation Challenge Now!

RESI on MaRS Innovation Challenge – Winners Announced

6 Apr

By Nono Hu, Director of Marketing, LSN

On April 4, more than 600 entrepreneurs and investors entered the exhibition hall at MaRS Discovery District in Toronto. They were greeted by 30 Innovation Challenge finalists across therapeutics, medical device, diagnostics, and healthcare IT sectors. The 30 companies, hand selected by LSN’s scientific and commercial review team, competed directly on merits of innovation and commercial viability. Here, LSN would like to present the top 3 winners who attracted the greatest amount of “RESI Cash”.

First Place: Steadiwear

Steadiwear inc.‘s mission is to restore independence and quality of life to all tremor sufferers worldwide. We have developed the Steadiglove, a smart glove that responsively stabilizes hand tremors in Essential Tremor and Parkinson’s disease using novel vibration damping technology. This allows users to go about all daily activities such as eating and getting dressed with significantly less frustration.

Michael Quigley, VP of Market Research, Life Science Nation | Mark Elias, CEO, Co-founder, Steadiwear | Emile Maamary, CFO, Co-founder | Natasha Eldridge, Marketing Manager – RESI Conference, Life Science Nation

Second Place: BlueLight

BlueLight is a healthcare technology company specializing in the measurement of light energy. Our data-driven technologies, sold worldwide, target a quality gap in the multi billion-dollar dental composite market.

Natasha Eldridge, Marketing Manager – RESI Conference, Life Science Nation | Michael Quigley, VP of Market Research, Life Science Nation | JP Furey, CEO, BlueLight | Peter MacLareN, Director of Customer Relations, BlueLight

Third Place: Cyclica

Cyclica Inc. has developed, validated, and patented a structure-based proteome-wide screening platform, Ligand Express™, that currently features PROBEx (proteome-screening), SWITCHx (ligand effect prediction) and DIVEx (systems biology & drug-protein interactomes). Ligand Express™ is unique in that it is a drug-centric platform. For a small molecule ligand, Ligand Express™ automatically generates an intelligent list of ligand-protein interactions by searching through a large proprietary database of all available structurally characterized proteins. The platform provides a panoramic view of a small molecule ligand to better understand on- and off-target interactions, and is valuable in finding novel desirable or undesirable targets. By gaining insights into a ligand’s polypharmacology, Cyclica’s clients can identify unknown targets, prioritize lead candidates, elucidate adverse effects, and understand repurposing opportunities.

Michael Quigley, VP of Market Research, Life Science Nation | Naheed Kurji, President and CEO, Cyclica | Natasha Eldridge, Marketing Manager – RESI Conference, Life Science Nation

Thank you to all who competed in the RESI on MaRS Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.

%d bloggers like this: